01530.HK
3SBio Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 13.54
−1.53%Year over year
Reported trailing growth
- Revenue
- +96.2%
- EBITDA
- +304.8%
- EBIT
- +355.3%
- EPS
- +238.8%
- Free cash flow
- +254.0%
- Operating cash flow
- +211.2%
Forward estimates
Based on analyst estimates
- Revenue
- -49.2%
- EBITDA
- -63.0%
- EPS
- -65.7%
Three-year CAGR
- Revenue
- +37.1%
- EBITDA
- +58.8%
- EBIT
- +72.1%
- Net income
- +64.2%
- EPS
- +63.8%
- Free cash flow
- +96.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026